ライフサイエンスコーパス: Gy

1 ssion of HDAC4 and then irradiated (2.5-10.0 Gy).

2 increased by 7.2 Gy, 10.9 Gy, 4.6 Gy and 2.0 Gy, respectively, in the SIB-IMRT plans.

3 was 34.2 Gy (interquartile range, 19.8-40.0 Gy).

4 omplete (45.0-50.4 Gy) and incomplete (<45.0 Gy) doses of radiation as preoperative therapy.

5 volume consisting of the pelvis (CTV1) (45.0 Gy) followed by a boost to the prostate bed (CTV2) (19.8

6 amous histology; median radiation dose, 63.0 Gy), and 3728 patients from 48 studies in carboplatin-pa

7 HF rate increased with MLVD: relative to 0 Gy, HF rates following MVLD of 1-15, 16-20, 21-25, and >

8 Nome of the LDIR-exposed mouse spleens (0.01 Gy, 6.5 mGy/h) was analyzed, and the expression of miRNA

9 mately 0.75 Gy/GBq, red marrow doses of 0.03 Gy/GBq, and salivary gland doses of 1.4 Gy/GBq, irrespec

10 ses (eg, heart mean dose; hazard ratio, 1.03/Gy; P = .002,), coronary artery disease ( P < .001), and

11 ar survival curve with alpha = 0.51 +/- 0.05 Gy(-1) and R(2) = 0.8838.

12 8.21; P = .04) and mean heart dose (HR, 1.07/Gy; 95% CI, 1.02 to 1.13/Gy; P = .01) were significantly

13 Here, we report that a 0.1 Gy radiation dose reduces cancer progression by deactiva

14 < 0.001) without a change in D0 (4.8 +/- 0.1 Gy).

15 , compared with 22.8 Gy for (111)In and 14.1 Gy for (161)Tb.

16 .8 after 0.2 Gy, and from 0.1 to 0.2 after 1 Gy IR for different cell lines.

17 Cells were exposed to 0, 0.2, or 1 Gy of X-rays, and the growth rates of cell populations w

18 not CCR7, TNF and IL1B was observed after 10 Gy cumulative doses, while anti-inflammatory markers CD1

19 Our observations indicate that at least 10 Gy are required.

20 Exposure to radiation doses of at least 10 Gy to the eyes increased the hazard ratio 39-fold (95% C

21 rates for patients with heart mean dose < 10 Gy, 10 to 20 Gy, or >/= 20 Gy were 4%, 7%, and 21%, resp

22 A total of 10 Gy irradiation was used to injure the intestinal epithel

23 5(Creert2)/Met(+/+)/LacZ) were exposed to 10 Gy total body irradiation; intestinal tissues were colle

24 Of the total dose of approximately 100 Gy, the first dose contributes 30%, the second dose 60%,

25 tion absorbed dose to tumor of more than 100 Gy would lead to a high probability of tumor cure while

26 ed doses to tumor derived from SPECT/CT (102 Gy) and from biodistribution (110 Gy) agreed to within 6

27 CT/CT (102 Gy) and from biodistribution (110 Gy) agreed to within 6.9%.

28 imated radiation absorbed dose to tumor, 110 Gy).

29 an (n = 25) or total body irradiation (>/=12 Gy; n = 18).

30 mula: see text] was 240 Gy for glass and 122 Gy for resin in TVs and 72 Gy for glass and 47 Gy for re

31 eart dose (HR, 1.07/Gy; 95% CI, 1.02 to 1.13/Gy; P = .01) were significantly associated with grade >/

32 low-up of 9 years and media boost dose of 14 Gy.

33 mulative risks of HF following MLVDs of 0-15 Gy, 16-20 Gy, and >/=21 Gy were 4.4%, 6.2%, and 13.3%, r

34 studies have shown that a single dose of 15 Gy of x-rays to the thorax causes severe pneumonitis in

35 ut 25% at 1, 2, and 3 wk after receipt of 15 Gy, and (99m)Tc-Duramycin uptake was more than doubled a

36 le dose of whole thorax irradiation (WTI, 15 Gy).

37 00 microm, 400 or 1200 microm and 360 or 150 Gy, respectively.

38 e microbeam path of rats irradiated with 150 Gy, whereas no increase was observed in rats irradiated

39 In, and (161)Tb were 96.5, 152, 153, and 152 Gy, respectively.

40 ho were randomized between no boost and a 16-Gy boost in the EORTC phase III "boost no boost" trial (

41 No further treatment or 16-Gy boost, after BCS and 50-Gy WBI.

42 leased per mum(3), which would result in 160 Gy if totally absorbed.

43 (IQR: 1.0 to 2.7) Gy and 98 (IQR: 57 to 168) Gy.cm(2), respectively.

44 x1 is induced by radiation doses above 12-18 Gy in different cancer cells, and attenuates their immun

45 and augmented postinduction therapy with 18 Gy of cranial radiation.

46 diated ones varied from 0.6 to 0.8 after 0.2 Gy, and from 0.1 to 0.2 after 1 Gy IR for different cell

47 daily for 5 days on weeks 4 and 8; hWBRT 1.2 Gy twice-daily on weeks 11 to 13 (36 Gy); and TMZ 200 mg

48 boost to the prostate bed (CTV2) (19.8-25.2 Gy).

49 who did not achieve complete dosing was 34.2 Gy (interquartile range, 19.8-40.0 Gy).

50 mor and ESOwhole-tumor were increased by 7.2 Gy, 10.9 Gy, 4.6 Gy and 2.0 Gy, respectively, in the SIB

51 ent and activated) undergo apoptosis after 2 Gy IR.

52 y (D)-7 to -3, melphalan 140 mg/m D-2, and 2 Gy TBI D-4 and -3.

53 ys, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after commencing cis

54 Moreover, exposure to 2 Gy IR promotes proliferation arrest and differentiation

55 ned (1:1) to either postoperative SRS (12-20 Gy single fraction with dose determined by surgical cavi

56 umors received a minimal tumor dose of 14-20 Gy.

57 isks of HF following MLVDs of 0-15 Gy, 16-20 Gy, and >/=21 Gy were 4.4%, 6.2%, and 13.3%, respectivel

58 After BEACOPPbaseline, 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84

59 rt mean dose < 10 Gy, 10 to 20 Gy, or >/= 20 Gy were 4%, 7%, and 21%, respectively.

60 cin, vinblastine, dacarbazine (ABVD) plus 20 Gy involved-field (IF)-RT to more intensive four cycles

61 ferior in ABVD-treated patients receiving 20 Gy instead of 30 Gy IF-RT (10-year PFS, 76% v 84%; HR, 1

62 ients with heart mean dose < 10 Gy, 10 to 20 Gy, or >/= 20 Gy were 4%, 7%, and 21%, respectively.

63 (OSC) including dexamethasone plus WBRT (20 Gy in five daily fractions) or OSC alone (including dexa

64 e effect can be detected for doses below 200 Gy.

65 lowing MLVDs of 0-15 Gy, 16-20 Gy, and >/=21 Gy were 4.4%, 6.2%, and 13.3%, respectively, in patients

66 uence, to receive immediate radiotherapy (21 Gy in three fractions within 42 days of the pleural inte

67 complete response (CR) to AV-PC received 21-Gy involved-field radiation therapy (IFRT).

68 n-absorbed doses to the tumor were 30 and 22 Gy for (177)Lu-T-AuNP and (177)Lu-NT-AuNP, respectively.

69 y in 12 fractions; the SRS dose was 18 to 22 Gy in the SRS plus WBRT group and 20 to 24 Gy for SRS al

70 2 Gy in the SRS plus WBRT group and 20 to 24 Gy for SRS alone.

71 The mean dose [Formula: see text] was 240 Gy for glass and 122 Gy for resin in TVs and 72 Gy for g

72 median MHD was 2.37 Gy (range, 0.51 to 15.25 Gy).

73 ase inhibition using AZ31 prior to 9 or 9.25 Gy total body irradiation (TBI) reduced median time to m

74 trioventricular junction (55, 50, 40, and 25 Gy).

75 Single-fraction doses as low as 25 Gy caused a lesion with interruption of cardiac impulse

76 ts were treated with a single fraction of 25 Gy while awake.

77 y along with involved-field radiotherapy (25 Gy) for early stage (IA, IB, and IIA) and advanced stage

78 lowing MVLD of 1-15, 16-20, 21-25, and >/=26 Gy were 1.27, 1.65, 3.84, and 4.39, respectively (Ptrend

79 [interquartile range, 24-44] for 1970s vs 26 Gy [interquartile range, 18-45] for 1990s).

80 C at the primary site or nodes received 69.3 Gy and cetuximab to those regions.

81 l was 75.2% after 4 Gy x 5 and 81.8% after 3 Gy x 10 (P = .51); 6-month overall survival was 42.3% an

82 an the bulk ROS sensor (detection limit of 3 Gy per droplet).

83 ssigned to 4 Gy x 5 in 1 week (n = 101) or 3 Gy x 10 in 2 weeks (n = 102).

84 4 Gy x 5 was not significantly inferior to 3 Gy x 10 in patients with MESCC and poor to intermediate

85 patients in Australia and New Zealand and 30 Gy in ten fractions over 2 weeks for patients in Canada

86 vinblastine, and dacarbazine) followed by 30 Gy involved site radiation therapy (ISRT).

87 0s vs 33% for 1990s), as did median dose (30 Gy [interquartile range, 24-44] for 1970s vs 26 Gy [inte

88 t of craniospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation).

89 HR, 1.6; 95% CI,1.0 to 2.6) and doses >/= 30 Gy (HR, 2.6; 95% CI, 1.6 to 4.2) were associated with an

90 Treatment with >/= 30 Gy CRT conferred greater risk of internalizing (OR, 1.7;

91 and receipt of craniospinal irradiation (<30 Gy or >30 Gy vs no craniospinal irradiation).

92 eated patients receiving 20 Gy instead of 30 Gy IF-RT (10-year PFS, 76% v 84%; HR, 1.5; 95% CI, 1.0 t

93 n-external-beam RT, and radiation dose of 30 Gy or lower or 70 Gy or higher.

94 o more intensive four cycles of ABVD plus 30 Gy IF-RT was confirmed with 10-year PFS of 87% each (HR,

95 T) scan (Deauville score of 1-3) received 30 Gy ISRT.

96 Pbaseline, 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84%; HR, 1.0; 95% CI, 0.7 to 1.5)

97 The WBRT dose schedule was 30 Gy in 12 fractions; the SRS dose was 18 to 22 Gy in the

98 mined by surgical cavity volume) or WBRT (30 Gy in ten daily fractions or 37.5 Gy in 15 daily fractio

99 t a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days to the chest wall and the draining regio

100 tectomy scar boost of four fractions of 3.33 Gy.

101 (HD) groups (</= or > median apex dose 84.35 Gy).

102 The radiotherapy dose was 35 Gy in 15 fractions over 3 weeks for patients in Australi

103 BRT 1.2 Gy twice-daily on weeks 11 to 13 (36 Gy); and TMZ 200 mg/m(2) daily for 5 days every 28 days

104 tients had craniospinal irradiation of 18-36 Gy radiobiological equivalents (GyRBE) delivered at 1.8

105 0 Gy whole-breast radiotherapy (control), 36 Gy whole-breast radiotherapy and 40 Gy to the partial br

106 ase was observed in rats irradiated with 360 Gy.

107 Results The median MHD was 2.37 Gy (range, 0.51 to 15.25 Gy).

108 The Dq values increased from 8.8 +/- 0.4 Gy to 10.5 +/- 0.5 Gy with AA-ORS treatment (P < 0.01),

109 reduced the BS/SC doses by approximately 1-4 Gy on average over the C-RA, with more MUs.

110 0.03 Gy/GBq, and salivary gland doses of 1.4 Gy/GBq, irrespective of tumor burden and consistent on s

111 ) was found for tumor doses of 12.4 and 16.4 Gy.

112 f low-dose total body irradiation (TBI) (2-4 Gy) to reduced intensity conditioning may reduce the rat

113 0 to 2015 were 5.7 Gy for whole lung and 4.4 Gy for whole heart.

114 eated with nCRT (carboplatin/paclitaxel/41.4 Gy) followed by esophagectomy.

115 In this study, we exposed mice to 0 or 5.4 Gy TBI, collected urine samples periodically over 1 year

116 LC was 50.4 Gy administered in 28 fractions during 5.5 weeks, with i

117 y 5.5 weeks of external-beam radiation (50.4 Gy delivered in 28 daily fractions) with capecitabine (8

118 orally twice daily) with radiotherapy (50.4 Gy in 1.8 Gy fractions daily, approximately 5 days conse

119 n days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions); and also did a second randomi

120 T was administered to a planned dose of 50.4 Gy in 28 fractions.

121 ving a target radiation dose of 45.0 to 50.4 Gy is associated with a survival benefit in patients wit

122 en patients who received complete (45.0-50.4 Gy) and incomplete (<45.0 Gy) doses of radiation as preo

123 axel (25 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions with or without weekly cetuximab (40

124 ve either conformal radiotherapy (up to 50.4 Gy; 28 doses of 1.8 Gy once daily, 5 days per week for u

125 ion technique, to receive radiotherapy (59.4 Gy in 33 fractions of 1.8 Gy) alone or with adjuvant tem

126 unit cord blood transplants, we have added 4 Gy TBI to the widely used fludarabine, melphalan conditi

127 progression-free survival was 75.2% after 4 Gy x 5 and 81.8% after 3 Gy x 10 (P = .51); 6-month over

128 xpected survival were randomly assigned to 4 Gy x 5 in 1 week (n = 101) or 3 Gy x 10 in 2 weeks (n =

129 Short-course RT with 4 Gy x 5 was not significantly inferior to 3 Gy x 10 in pa

130 izing radiations down to the level of 10(-4) Gy, representing a significant improvement on the detect

131 oplatin plus paclitaxel with concurrent 41.4-Gy radiotherapy) followed by surgery or surgery alone.

132 nse prediction was 90 Gy for remnants and 40 Gy for metastases.

133 rol), 36 Gy whole-breast radiotherapy and 40 Gy to the partial breast (reduced-dose group), or 40 Gy

134 e every 2 weeks, followed or not by RT at 40 Gy delivered 4 weeks after the last R-CHOP cycle.

135 After targeted irradiation (40 Gy) of the skin of wild-type (WT) or A2AR knockout (A2AR

136 group 1 received the lowest dose (>30 to <40 Gy); group 2, the next lowest (40 to <50 Gy); group 3, t

137 e partial breast (reduced-dose group), or 40 Gy to the partial breast only (partial-breast group) in

138 were randomly assigned (1:1:1) to receive 40 Gy whole-breast radiotherapy (control), 36 Gy whole-brea

139 < .05), and the volume of heart receiving 40 Gy (V40) was significantly associated with OS on adjuste

140 ladder, and penile bulb volumes receiving 40 Gy and 60 Gy demonstrated that only the penile bulb volu

141 , and penile bulb), the volumes receiving 40 Gy and 65 Gy before registration were compared with thos

142 om 33 [19-55] Gy cm(2) in 2009 to 27 [16-44] Gy cm(2) in 2013 for CA (P<0.0001), and from 73 [41-125]

143 received preoperative chemoradiotherapy (45 Gy in 25 daily fractions with concurrent fluoropyrimidin

144 were randomly assigned to receive either 45 Gy radiotherapy in 30 twice-daily fractions of 1.5 Gy ov

145 and metabolic activity after delivery of 45 Gy of fractionated radiatiotherapy (RT), and that metabo

146 for resin in TVs and 72 Gy for glass and 47 Gy for resin in NTVs.

147 ow was dose dependent, with as little as 0.5 Gy causing a significant long-term reduction.

148 atory-disease mortality associated with <0.5 Gy radiation exposure in a pooled cohort of 63,707 patie

149 Under 0.5 Gy there are increasing trends for all circulatory disea

150 ncreased from 8.8 +/- 0.4 Gy to 10.5 +/- 0.5 Gy with AA-ORS treatment (P < 0.01), indicating an incre

151 Risks associated with lower-dose (<0.5 Gy) exposures remain unclear, with little information on

152 sease mortality radiation risk at doses <0.5 Gy.

153 ver a wide range of ages, many at doses <0.5 Gy.

154 iotherapy in 30 twice-daily fractions of 1.5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of

155 ions or 37.5 Gy in 15 daily fractions of 2.5 Gy; fractionation schedule predetermined for all patient

156 r WBRT (30 Gy in ten daily fractions or 37.5 Gy in 15 daily fractions of 2.5 Gy; fractionation schedu

157 Solar System's earliest ( approximately 4.5 Gy) chemical and physical processes.

158 platin (0.7 or 7 muM) or radiation (2 or 4.5 Gy).

159 adiation-induced hematopoietic syndrome (6.5 Gy exposure, LD50/30).

160 oton therapy to a maximum total dose of 67.5 Gy equivalent.

161 A BED greater than 80.5 Gy seems to be an ablative dose of RT for large IHCCs, w

162 y higher (78%) after a BED greater than 80.5 Gy than after lower doses (45%, P = .04).

163 for patients receiving BED greater than 80.5 Gy was 73% versus 38% for those receiving lower doses (P

164 the volume of the left ventricle receiving 5 Gy (LV-V5) was the most important prognostic dose-volume

165 SC consisted of pelvic radiotherapy 5 x 5 Gy in 1 week, early surgery and 6 courses of adjuvant ch

166 e completion of adjuvant radiotherapy (42.50 Gy in 16 fractions to the breast), the patient has retur

167 the receipt of radical cystectomy or >/= 50 Gy of radiation therapy delivered to the bladder, affect

168 esection of the bladder tumor alone, or < 50 Gy of radiation therapy delivered to the bladder were in

169 <40 Gy); group 2, the next lowest (40 to <50 Gy); group 3, the second highest dose (50 to 55 Gy); and

170 he effect of a reduced dose of radiation, 50 Gy (relative biological effectiveness [RBE]) versus 70 G

171 two-thirds (70.4%) of patients receiving 50 Gy (RBE) and nearly half (45.1%) of patients receiving 7

172 Adjuvant RT dose from 40 to lower than 50 Gy appears adequate for extremities and/or trunk stage I

173 lower rectum who had received RCT (45 to 50 Gy with fluorouracil or capecitabine) were included.

174 r treatment or 16-Gy boost, after BCS and 50-Gy WBI.

175 rapy and 133 underwent chemoradiotherapy (54 Gy plus capecitabine).

176 patients continued to cetuximab with IMRT 54 Gy.

177 ensity-modulated radiation therapy (IMRT) 54 Gy with weekly cetuximab; those with less than cCR to IC

178 atients treated with a radiation dose </= 54 Gy had difficulty swallowing solids (40% v 89%; P = .011

179 smoking history who were treated with </= 54 Gy of radiation (n = 27).

180 igh-precision SCRT or ConvRT to a dose of 54 Gy in 30 fractions over 6 weeks.

181 onders to induction chemotherapy received 54 Gy in 27 fractions, and those with less than partial or

182 ponses to induction chemotherapy received 54 Gy radiation, and 20 (45%) with less than partial respon

183 CAC and HIV infection received CRT: 45 to 54 Gy radiation therapy to the primary tumor and regional l

184 ary tumor and regional lymph nodes (45 to 54 Gy) plus eight once-weekly doses of concurrent cetuximab

185 tients with primary-site cCR treated with 54 Gy of radiation (n = 51); 96% and 96%, respectively, for

186 High doses (40-55 Gy) caused slowing and interruption of cardiac impulse p

187 Doses of 25, 40, and 55 Gy were applied in forced-breath-hold to the atrioventri

188 With doses of </=55 Gy, maximal point-doses to coronary arteries could be ke

189 ; group 3, the second highest dose (50 to 55 Gy); and group 4, the highest dose (>55 to 70 Gy).

190 a area product was observed, from 33 [19-55] Gy cm(2) in 2009 to 27 [16-44] Gy cm(2) in 2013 for CA (

191 065 patients; 60 Gy group, 1074 patients; 57 Gy group, 1077 patients).

192 % (95 events) and 6.6% (57 events) in the 57 Gy group, respectively.

193 60 Gy group, and 85.9% (83.4-88.0) in the 57 Gy group.

194 9 min (p < 0.0001) and 65 Gy.cm(2) versus 59 Gy.cm(2) (p = 0.0001), respectively.

195 Normal organ doses were low (0.04-0.6 Gy).

196 d with radiation therapy (RT), doses >/=30.6 Gy were associated with a significantly better complete

197 tumor were increased by 7.2 Gy, 10.9 Gy, 4.6 Gy and 2.0 Gy, respectively, in the SIB-IMRT plans.

198 amous histology; median radiation dose, 64.6 Gy).

199 g of the prostate bed alone (CTV) (64.8-66.6 Gy).

200 g of the prostate bed alone (CTV) (64.8-66.6 Gy).

201 nd pancreas cells were exposed to 2, 4 and 6 Gy IR doses and expression of fourteen HKGs was measured

202 al cancer brachytherapy plans giving D90 < 6 Gy (with 7 Gy per fraction) at our institution.

203 nservatively estimated at a minimum of 40-60 Gy.

204 d penile bulb volumes receiving 40 Gy and 60 Gy demonstrated that only the penile bulb volumes were s

205 ents who had received 100% of the dose of 60 Gy external beam radiation to the macular area were incl

206 over 8 weeks or to hypofractionated RT of 60 Gy in 20 fractions over 4 weeks.

207 received the uniform prescription dose of 60 Gy to the planning target volume.

208 mly assigned (74 Gy group, 1065 patients; 60 Gy group, 1074 patients; 57 Gy group, 1077 patients).

209 ess than partial or no responses received 60 Gy in 30 fractions.

210 with less than partial responses received 60 Gy.

211 (105 events) and 11.7% (88 events) in the 60 Gy group, 11.3% (95 events) and 6.6% (57 events) in the

212 the 74 Gy group, 90.6% (88.5-92.3) in the 60 Gy group, and 85.9% (83.4-88.0) in the 57 Gy group.

213 Hypofractionated radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fract

214 res were comparable between the 74-Gy and 60-Gy arms.

215 ore patients in the 74-Gy arm than in the 60-Gy arm had clinically meaningful decline in FACT-LCS at

216 Treatment with 74-Gy vs 60-Gy RT with concurrent and consolidation carboplatin/pacl

217 weeks) or hypofractionated radiotherapy (62 Gy in 20 fractions in 5 weeks) to prostate and seminal v

218 Methods We delivered PMRT at a dose of 36.63 Gy in 11 fractions of 3.33 Gy over 11 days to the chest

219 le bulb), the volumes receiving 40 Gy and 65 Gy before registration were compared with those after re

220 ess: 10 min versus 9 min (p < 0.0001) and 65 Gy.cm(2) versus 59 Gy.cm(2) (p = 0.0001), respectively.

221 achieved at an AD threshold range of 350-650 Gy.

222 One toxic death (66 Gy) and 1 case of grade 4 pneumonitis (>66 Gy) were repo

223 6 Gy) and 1 case of grade 4 pneumonitis (>66 Gy) were reported.

224 aily fractions of 1.5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, star

225 If there was no uptake, 66 Gy were delivered.

226 OS; androgen suppression and SRT doses > 68 Gy were associated with BcR; and age was associated with

227 rior clinical trial experience with 63 to 69 Gy in a similar patient population.

228 ting an increased radiation tolerance of 1.7 Gy.

229 Average MLVD was 16.7 Gy for cases and 13.8 Gy for controls (Pdifference = .00

230 imens published during 2010 to 2015 were 5.7 Gy for whole lung and 4.4 Gy for whole heart.

231 rachytherapy plans giving D90 < 6 Gy (with 7 Gy per fraction) at our institution.

232 ose area product) were 1.6 (IQR: 1.0 to 2.7) Gy and 98 (IQR: 57 to 168) Gy.cm(2), respectively.

233 low-risk prostate cancer, the efficacy of 70 Gy in 28 fractions over 5.6 weeks is not inferior to 73.

234 , and radiation dose of 30 Gy or lower or 70 Gy or higher.

235 nearly half (45.1%) of patients receiving 70 Gy (RBE) retained 20/200 or better vision 5 years after

236 41 fractions over 8.2 weeks) or to H-RT (70 Gy in 28 fractions over 5.6 weeks).

237 (arm A) vs accelerated-fractionation RT (70 Gy/35 over 6 weeks) plus panitumumab at 9 mg/kg intraven

238 (arm A) vs accelerated-fractionation RT (70 Gy/35 over 6 weeks) plus panitumumab at 9 mg/kg intraven

239 1:1 to receive standard-fractionation RT (70 Gy/35 over 7 weeks) plus cisplatin at 100 mg/m2 intraven

240 1:1 to receive standard-fractionation RT (70 Gy/35 over 7 weeks) plus cisplatin at 100 mg/m2 intraven

241 hat found at higher-dose regimens (>50 to 70 Gy).

242 y); and group 4, the highest dose (>55 to 70 Gy).

243 Proton beam irradiation (total 70 Gy) delivered in 5 equal fractions.

244 ve biological effectiveness [RBE]) versus 70 Gy (RBE), on visual outcomes was analyzed.

245 Median prescription dose was 70 Gy, 84% received concurrent chemotherapy, and 27% had pr

246 for glass and 122 Gy for resin in TVs and 72 Gy for glass and 47 Gy for resin in NTVs.

247 ed from 71 centres and randomly assigned (74 Gy group, 1065 patients; 60 Gy group, 1074 patients; 57

248 dose-escalated RT to 70 to 90 Gy (median, 74 Gy) in six trials.

249 (111 events) and 9.1% (66 events) in the 74 Gy group, 11.9% (105 events) and 11.7% (88 events) in th

250 years was 88.3% (95% CI 86.0-90.2) in the 74 Gy group, 90.6% (88.5-92.3) in the 60 Gy group, and 85.9

251 erior to conventional fractionation using 74 Gy in 37 fractions and is recommended as a new standard

252 -paclitaxel) and passively scattered PBT (74-Gy relative biological effectiveness) in all patients.

253 ne QOL scores were comparable between the 74-Gy and 60-Gy arms.

254 inically meaningful decline in QOL in the 74-Gy arm at 3 months, confirming the primary QOL hypothesi

255 Significantly more patients in the 74-Gy arm than in the 60-Gy arm had clinically meaningful d

256 with or without cetuximab, and 60- versus 74-Gy radiation doses.

257 Treatment with 74-Gy vs 60-Gy RT with concurrent and consolidation carbopl

258 revealed kidney doses of approximately 0.75 Gy/GBq, red marrow doses of 0.03 Gy/GBq, and salivary gl

259 ents were allocated to conventional RT of 78 Gy in 39 fractions over 8 weeks or to hypofractionated R

260 Centers opted for one dose (70, 74, or 78 Gy).

261 ice daily) with radiotherapy (50.4 Gy in 1.8 Gy fractions daily, approximately 5 days consecutively p

262 5 mg/m2), and daily radiation of 50.4 Gy/1.8 Gy fractions with or without weekly cetuximab (400 mg/m2

263 radiotherapy (up to 50.4 Gy; 28 doses of 1.8 Gy once daily, 5 days per week for up to 6.5 weeks) or d

264 radiotherapy (59.4 Gy in 33 fractions of 1.8 Gy) alone or with adjuvant temozolomide (12 4-week cycle

265 Average MLVD was 16.7 Gy for cases and 13.8 Gy for controls (Pdifference = .003).

266 177)Lu delivered 3.92 Gy, compared with 22.8 Gy for (111)In and 14.1 Gy for (161)Tb.

267 lations showed a tumor-absorbed dose of 43.8 Gy per millicurie injected dose of (90)Y, with tumor-to-

268 cer were randomly assigned 1:1 to C-RT (73.8 Gy in 41 fractions over 8.2 weeks) or to H-RT (70 Gy in

269 tions over 5.6 weeks is not inferior to 73.8 Gy in 41 fractions over 8.2 weeks, although an increase

270 After a single dose of radiation (8 Gy), several ceramide species were significantly elevate

271 Patients were treated with a single 8-Gy radiotherapy dose for 1 or 2 bone metastases.

272 A single 8-Gy radiotherapy dose for bone metastases should be offer

273 assigned in a 1:1 ratio to conventional (80 Gy in 40 fractions in 8 weeks) or hypofractionated radio

274 ose iodine-125 plaque brachytherapy (67.5-81 Gy at tumor apex) provides safe and effective tumor cont

275 Median tumor dose delivered was 83 Gy (range, 63-86 Gy) in 30 daily fractions.

276 tumor dose delivered was 83 Gy (range, 63-86 Gy) in 30 daily fractions.

277 idtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions.

278 of whom received escalated doses of up to 86 Gy.

279 t be reversed by radiotherapy doses up to 86 Gy.

280 SOwhole-tumor were increased by 7.2 Gy, 10.9 Gy, 4.6 Gy and 2.0 Gy, respectively, in the SIB-IMRT pla

281 gioma compared with CRT doses of 1.5 to 19.9 Gy ( P < .001).

282 CRT doses of 20 to 29.9 Gy (HR, 1.6; 95% CI,1.0 to 2.6) and doses >/= 30 Gy (HR,

283 higher radiation-absorbed dose (55.0 vs. 5.9 Gy, respectively).

284 rage absorbed doses of between 35.5 and 91.9 Gy to the gastric wall.

285 to 1) received dose-escalated RT to 70 to 90 Gy (median, 74 Gy) in six trials.

286 correct complete response prediction was 90 Gy for remnants and 40 Gy for metastases.

287 <0.0001), and from 73 [41-125] to 55 [31-91] Gy cm(2) for PCI (P<0.0001).

288 ce, in a 10-mum cell, (177)Lu delivered 3.92 Gy, compared with 22.8 Gy for (111)In and 14.1 Gy for (1

289 at treatment (ERR/Gy(<27.5years), 20.0%; ERR/Gy(27.5-36.4years), 8.8%; ERR/Gy(36.5-50.9years), 4.2%;

290 s), 20.0%; ERR/Gy(27.5-36.4years), 8.8%; ERR/Gy(36.5-50.9years), 4.2%; P(interaction) = .149).

291 e with each tertile of age at treatment (ERR/Gy(<27.5years), 20.0%; ERR/Gy(27.5-36.4years), 8.8%; ERR

292 umulating X-ray dose-levels above 2000 Gray (Gy).

293 tive incidence of ACE increased by 16.5% per Gy (95% CI, 0.6 to 35.0; P = .042).

294 h 123 in bulk increased at a rate of 54% per Gy of X-ray radiation and 15% per MBq/ml of 2-deoxy-2-[(

295 ndicated 0.04 (95% CI, 0.02 to 0.06) ERR per Gy whole-heart dose.

296 dicating 0.11 (95% CI, 0.05 to 0.20) ERR per Gy whole-lung dose.

297 Third, the lung or heart ERRs per Gy in the trials and the 2010 to 2015 doses were combine

298 specific mortality and excess RRs (ERRs) per Gy for incident lung cancer and cardiac mortality.

299 Using MHD, the relative increase per Gy was similar to that reported in the previous study.

300 ry disease (n = 10,209; excess relative risk/Gy = 0.246; 95% CI 0.036, 0.469; p = 0.021) and for isch

301 eart disease (n = 6410; excess relative risk/Gy = 0.267; 95% CI 0.003, 0.552; p = 0.048).

302 Studies with Gy mice and human patients with the very rare X-linked g